Clinical trial
Baseline Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With FDA-approved Disease-Modifying Therapies
NCT06459232 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Baseline Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With FDA-approved Disease-Modifying Therapies
- Lead sponsor
- Novartis
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 19, 2020
- Completion date
- December 17, 2021
- Enrollment
- 143 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.